Review anchor
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
Evidence Snapshot
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform
CHEMBL4004
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform as ChEMBL target CHEMBL4004, mapped to UniProt Q16816. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL4004
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q16816
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform
UniProt accession via ChEMBL component mapping
As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-14
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform matters
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform is reviewed as Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform (UniProt Q16816); the current evidence base includes 9 approved drugs, 762 compounds, and 187 assays, with lead potency reaching pChEMBL 9.4.
Protein context
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform Sequence length is 387 aa.
Review this target as Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform, mapped to UniProt Q16816. Sequence length is 387 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q16816
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 9 approved drugs, 762 compounds, and 187 assays for this target. The dominant activity type is KD. CHEMBL603469 is the current potency anchor at pChEMBL 9.4.
Use CHEMBL603469 as the tractability anchor when discussing potency (pChEMBL 9.4).
Activity source · ChEMBL 36 via Core Engine
9 approved
pChEMBL 9.4
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q16816, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
762
Total Compounds
187
Total Assays
9
Approved Drugs
IC50: 17.0, KD: 143.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL603469
|
9.4 | Kd | Clinical |
|
|
No preferred name
CHEMBL388978
|
9.3 | Kd | — |
|
|
No preferred name
CHEMBL4465866
|
9.0 | Kd | — |
|
|
No preferred name
CHEMBL388978
|
8.7 | IC50 | — |
|
|
No preferred name
CHEMBL4576489
|
8.5 | Kd | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
FEDRATINIB
CHEMBL1287853
|
2019 |
|
|
MIDOSTAURIN
CHEMBL608533
|
2017 |
|
|
NINTEDANIB
CHEMBL502835
|
2014 |
|
|
BOSUTINIB
CHEMBL288441
|
2012 |
|
|
SUNITINIB
CHEMBL535
|
2006 |
Source Header